Parnax Lab cash flow

Latest FY25

Cash from operations: ₹0.3cr+234.4% on FY24
Capital spending: ₹0.0cr−100.0% on FY24
Free cash flow: ₹0.3cr−₹0.0 cr in FY24
Cash from financing: −₹0.0cr−₹1.2 cr in FY24

₹ crore except per share

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022	FY21 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items					FY21 and earlierEvery year the company has filed comes with Alpha Plus.
	0.1	0.1	0.1	0.0
	0.0	0.1	0.2	0.7
	0.1	−0.3	0.2	−0.2
	−0.3	0.5	0.8	−1.4
	0.6	0.3	−0.7	−0.1
Cash from operating activities
	1.9	2.4	1.6	0.8
	0.3	0.1	−0.3	−0.4
	0.0	0.0	0.0	0.0
	0.3	0.1	−0.3	−0.4
Cash from investing activities
	0.0	0.1	0.1	—
	0.1	0.2	—	—
	−0.2	0.3	0.1	—
Cash from financing activities
	0.0	0.2	1.0	0.7
	−0.0	−1.2	−2.9	4.6
	0.1	−0.8	−3.1	4.2
	0.5	0.4	1.3	4.3
Reference items
	1.2	2.1	1.6	1.4
	17.6%	28.4%	21.1%	19.1%
	0.3	−0.0	−0.3	−0.4
	0.0	0.0	0.0	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PARNAXLAB₹103.25

Parnax Lab Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	0.0	0.1	0.1	0.1
+ Finance Costs	0.7	0.2	0.1	0.0
Changes in Working Capital
+ Inventories	-0.2	0.2	-0.3	0.1
+ Trade Receivables — Current	-1.4	0.8	0.5	-0.3
+ Trade Payables — Current	-0.1	-0.7	0.3	0.6
Cash from Operating Activities
Profit Before Tax (per I/S)	0.8	1.6	2.4	1.9
Cash from Operations (pre-tax)	-0.4	-0.3	0.1	0.3
+ Income Taxes Paid	0.0	0.0	0.0	0.0
Cash from Operating Activities	-0.4	-0.3	0.1	0.3
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	—	0.1	0.1	0.0
+ Disp of Fixed Assets	—	—	0.2	0.1
Cash from Investing Activities	—	0.1	0.3	-0.2
Cash from Financing Activities
+ Proceeds from Borrowings	0.7	1.0	0.2	0.0
Cash from Financing Activities	4.6	-2.9	-1.2	-0.0
Net Changes in Cash	4.2	-3.1	-0.8	0.1
Closing Cash	4.3	1.3	0.4	0.5
Reference Items
EBITDA	1.4	1.6	2.1	1.2
EBITDA Margin %	19.14	21.05	28.37	17.61
Free Cash Flow (CFO − Capex)	-0.4	-0.3	-0.0	0.3
Cash Paid for Taxes	0.0	0.0	0.0	0.0

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.